- Published on
Toxicology – Nerve Agent Toxicity
Source
Nerve agents are highly toxic chemicals developed for warfare and terrorist use. They are classified into two main groups:
Typical Presentation
Exposure typically occurs via inhalation, skin contact, or ingestion. Patients often present rapidly with symptoms of excessive cholinergic activity affecting multiple organ systems.
Clinical Features
Findings are consistent with a cholinergic toxidrome. Common features include pinpoint pupils (miosis), slow heart rate (bradycardia), excessive secretions (salivation, tearing, bronchorrhea), bronchospasm, vomiting, diarrhea, and urination. Neuromuscular effects include muscle twitching (fasciculations), weakness, seizures, and coma. Respiratory failure is a major cause of death.
Mechanism of Action
Nerve agents are organophosphate compounds that irreversibly inhibit acetylcholinesterase. This leads to accumulation of acetylcholine at synapses, resulting in continuous stimulation of both muscarinic and nicotinic receptors. Over time, the enzyme–toxin complex undergoes “aging,” making inhibition permanent.
Management
Immediate removal from the exposure source and decontamination are critical. Atropine is administered to counteract muscarinic effects by blocking acetylcholine receptors. Pralidoxime (2-PAM) can reactivate acetylcholinesterase if given early, before aging occurs. Benzodiazepines are used to control seizures. Supportive care, including airway management, is essential.
Key Points
Source
Nerve agents are highly toxic chemicals developed for warfare and terrorist use. They are classified into two main groups:
- G-series agents (developed in Germany): tabun (GA), sarin (GB), soman (GD), and cyclosarin (GF)
- V-series agents (developed in the United Kingdom): VE, VG, VM, VR, and VX
Typical Presentation
Exposure typically occurs via inhalation, skin contact, or ingestion. Patients often present rapidly with symptoms of excessive cholinergic activity affecting multiple organ systems.
Clinical Features
Findings are consistent with a cholinergic toxidrome. Common features include pinpoint pupils (miosis), slow heart rate (bradycardia), excessive secretions (salivation, tearing, bronchorrhea), bronchospasm, vomiting, diarrhea, and urination. Neuromuscular effects include muscle twitching (fasciculations), weakness, seizures, and coma. Respiratory failure is a major cause of death.
Mechanism of Action
Nerve agents are organophosphate compounds that irreversibly inhibit acetylcholinesterase. This leads to accumulation of acetylcholine at synapses, resulting in continuous stimulation of both muscarinic and nicotinic receptors. Over time, the enzyme–toxin complex undergoes “aging,” making inhibition permanent.
Management
Immediate removal from the exposure source and decontamination are critical. Atropine is administered to counteract muscarinic effects by blocking acetylcholine receptors. Pralidoxime (2-PAM) can reactivate acetylcholinesterase if given early, before aging occurs. Benzodiazepines are used to control seizures. Supportive care, including airway management, is essential.
Key Points
- Rapid onset and high lethality require immediate intervention.
- G-series agents are volatile; V-series agents are persistent and more difficult to remove.
- Early administration of pralidoxime is crucial before irreversible enzyme inhibition occurs.
- Respiratory failure is the primary life-threatening complication.
0 Comments
